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Prolonged QTc intervals can lead to ventricular tachy- 
arrhythmia and TdP. While the true incidence of TdP is un-
known, the number of reported cases is low. Over a period 
of 15 years only 761 cases were reported to the World Health 
Organization.5 Therefore, prolonged QTc has become a 
surrogate marker for TdP.1,5 
It is important to note that drug induced QTc prolonga-
tion alone rarely leads to TdP. A review of population studies 
reported prolonged QTc was associated with TdP in pa-
tients with preexisting cardiovascular disease, but not with 
healthy patients.6 Rather TdP is most likely to occur when 
prolonged QTc is combined with at least two risk factors 
such as electrolyte abnormalities, bradycardia or congeni-
tal cardiac abnormalities. The most important risk factors 
appear to be preexisting heart disease, age >65 years, and 
female sex. 6,7 Torsades de pointes may be increased in hos-
pitalized patients because hospitalized patients are more 
likely to have risk factors such as heart disease, advanced age, 
bradycardia or electrolyte disturbances than outpatients.8 
QTc prolongation is often dose dependent but the max-
imal effect of many drugs is limited.6 Therefore, massive 
drug overdoses of QTc prolonging medications do not 
necessarily result in severe QTc prolongation or TdP. 
Psychotropics and QTc
Psychotropics, such as antidepressants and antipsychotics, 
affect the heart by blocking certain potassium channels. 
This leads to a blockade of type IKr (a fast potassium chan-
nel in the heart), causing a delay in repolarization and thus 
QTc prolongation.1,2 This is accomplished via either HERG 
(Human ether-a-go-go Related Gene) blockade or abnormal 
protein trafficking for HERG. Almost all drugs which can 
induce TdP block HERG, while a few indirectly affect HERG 
function.1,2 Drugs which prolong the QTc by alternate means 
are less likely to result in TdP.
ABSTRACT 
Over the past two decades there has been a large increase 
in the number of patients prescribed psychotropic med-
ications. Many of these agents are associated with QTc 
prolongation which is considered a marker for increased 
risk of sudden cardiac death due to malignant arrhyth-
mias such as Torsades de pointes (TdP). Psychotropics 
rarely lead to sudden death in healthy individuals on a 
single QTc prolonging medication. However, factors such 
polypharmacy, recent initiation of a QTc prolonging med-
ication, bradycardia, electrolyte abnormalities and preex-
isting arrhythmias increase the likelihood of psychotro-
pic-induced sudden cardiac death. Therefore, clinicians 
must recognize which psychotropics and risk factors are 
associated with increased risk in order to minimize the 
risks of psychotropic QTc prolongation.
KEYWORDS:  psychotropic, side effect, cardiac, QTc, 
Torsades, arrhythmia
INTRODUCTION
There has been increasing concern regarding the cardiac side 
effects of psychotropics. Some psychotropic medications in-
crease the risk of sudden cardiac death. However, these drugs 
are important for many patients. Therefore, it is important 
to assess cardiac risks associated with psychotropics. This 
article will summarize these effects and provide recommen-
dations on cardiac risk assessment for patients treated with 
psychotropic medications. 
The QT interval and Torsades de pointes
The QT interval is the measure of cardiac conduction speed 
that starts from the beginning of a QRS wave and ends with 
the T wave on an electrocardiogram (ECG). Usually the 
length of the QT wave decreases as heart rate increases, so 
a corrected value (QTc) is used to assess cardiac conduction. 
QTc is measured in milliseconds and the average QTc is be-
tween 430 and 450 milliseconds. (Table 1) Females usually 
have a slower cardiac conduction rhythm than males and 
thus a longer QTc.1-3 The QTc varies by up to 10 milliseconds 
during the course of a day with maximal intervals during the 
first few hours of awakening.4 
Table 1. Average QTc1-3
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 MEN WOMEN 
NORMAL <430 <450 
BORDERLINE 431-450 451-470 
PROLONGED >450 >470 
with preexisting risk factors or those with elevated blood 
concentrations due to over dose, high doses or drug inter-
actions. Bupropion, mirtazapine and trazodone all appear to 
have minimal risk of QTc prolongation at typical doses.15
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Population-based studies indicate there is a two- to three-
fold increased risk of sudden cardiac death in patients taking 
non-cardiac QTc prolonging medications.6,7 Antidepressants 
are the psychotropic class most commonly associated with 
TdP (9%).7,9,10 For antipsychotics, it is estimated there are 
10-15 sudden cardiac deaths/10,000 years of observation, 
and only a small proportion of these deaths are likely attrib-
utable to TdP.11 Risk of QTc prolongation with other psycho-
tropics such as benzodiazepines and anticonvulsants is low. 
Risk is of sudden cardiac death is highest in the first 90 
days of initiating, increasing the dose or adding an interact-
ing medication. Female sex, polypharmacy, congenital long 
QT syndrome, electrolyte abnormalities, increasing age and 
higher doses of QTc prolonging medication all increase the 
likelihood of experiencing drug induced QTc prolongation.10,11 
While studies have reported psychotropics increase pa-
tients’ average QTc, the QTc interval typically remains less 
than 500 milliseconds, considered a clinically relevant in-
dicator of TdP risk.4,10,11 In patients with schizophrenia a 
reported history of arrhythmia and other metabolic factors 
had greater influence on the prolongation of QTc interval 
than use of psychotropics alone.9 Therefore, it seems likely 
psychotropic induced QTc prolongation is unlikely to lead 
to TdP in the absence of other risk factors. 
Antipsychotics and QTc 
Although large epidemiologic studies have reported first- 
and second-generation antipsychotics are associated with 
increased risk of sudden cardiac death, the absolute risk of 
death remains quite low.1,3,6,7,9-14 In addition, while numer-
ous antipsychotics have been shown to prolong the QTc 
(Table 2), relatively few antipsychotics have been associated 
with TdP.1,3,13,14 Thioridazine, pimozide and ziprasidone are 
known to cause the greatest QTc prolongation while queti-
apine, risperidone and clozapine are associated with lower 
risk.1,12-14 Significant evidence of antipsychotic induced TdP 
is only associated with mesoridazine, thioridazine and hal-
operidol.1,15 While haloperidol has been linked to TdP, risk 
is much lower than with thioridazine.1,13,14 Aripiprazole 
appears to have a lower risk of QTc prolongation, although 
there is one well documented case report of QTc pro- 
longation with low dose monotherapy aripiprazole.13-16
Antidepressants and QTc
Large epidemiologic trials have demonstrated an elevated 
risk of sudden cardiac death with tricyclic antidepressants 
(TCAs). TCAs have been shown to prolong the QTc 10-25 ms 
and cases of TdP have been reported with most, although not 
all, TCAs.13-15 Newer antidepressants have less risk of QTc 
prolongation and sudden cardiac death compared with TCAs 
although QTc prolongation of 5-12 ms and cases of TdP have 
been reported for citalopram, fluoxetine and paroxetine.13-15 
Reports of QTc prolongation are mixed with the serotonin 
norepinepherine reuptake inhibitors (SNRIs). However, for 
both SSRIs and SNRIs, risk appears to be greatest in patients 
Table 2. Mean QTc prolongation and psychotropics12-15
DRUG MEAN QTc  (msec) 
ANTIDEPRESSANTS 
TCAs >16 
Mirtazapine 5-8 
Trazodone 5-8 
Venlafaxine 4.7 
Duloxetine 0 
Fluoxetine 9-16 
Citalopram  8-10 
Escitalopram 4.5 
Paroxetine 1 – 4 
Fluvoxamine 0-2 
Sertraline 0 
Bupropion 0 
ANTIPSYCHOTICS 
Thioridazine 25-30 
Ziprasidone 5-22 
Pimozide 13 
Clozapine 8-10 
Iloperidone 9 
Haloperidol 7 
Quetiapine 6 
Risperidone  0-5 
Olanzapine 2 
Asenapine 2-5 
Aripiprazole 0 
 
medication is increased, a pre- and post-baseline ECG will 
be useful in determining risk of the dose increase.
For patients with a prolonged QTc of ≥ 500 milliseconds, 
consider discontinuing any QTc prolonging medications 
and/or substituting with medications less likely to prolong 
the QTc. Also, consider consulting a cardiologist. 
SUMMARY
Since psychotropic-induced QTc prolongation is typically 
dose related, patients should be maintained on the lowest 
effective doses of psychotropics. Additionally, careful review 
for drug interactions should be conducted prior to adding any 
medications to ongoing psychotropic treatment. The risk of 
psychotropic-induced QTc prolongation is highest when a 
medication is started, reaches steady state or after dose in-
creases. Therefore, patients successfully treated for >90 days 
are less likely to experience psychotropic induced arrhyth-
mias unless there are changes in medication treatment or 
new risk factors. Sudden cardiac death is unlikely in patients 
without preexisting risk factors and is a rare outcome for those 
with risk factors. Even for patients with risk factors who may 
have a prolonged QTc that is < 500 milliseconds, treatment 
with a psychotropic may be reasonable with appropriate 
monitoring. Physicians should not be discouraged from psy-
chotropic use unless patients have a contraindication, such 
as a cardiac arrhythmia or congenital long QT syndrome. 
References
1. Huffman JC, Stern TA. QTc Prolongation and the Use of Anti-
psychotics: A Case Discussion. Prim Care Companion J Clin 
Psychiatry. 2003;5(6):278-281.
2. Ponte ML, Keller GA, Di Girolama G. Mechanism of Drug 
Induced QT Interval Prolongation. Current Drug Safety. 
2010;5:44-53.
3. Yap YG, Cramm AJ. Drug Induced QT Prolongation and tor-
sades de pointes. Heart. 2003;89(11):1363-1372.
4. Nielsen J, Graff C, Kanters JK, Toft E, Taylor D, Meyer JM. As-
sessing the QT interval prolongation and its associated risks 
with antipsychotics. CNS Drugs. 201;25(6):473-490.
5. Darpo B. Spectrum of drugs prolonging QT interval and 
the incidence of torsades de pointes. Eur Heart J (Suppl K). 
2001;3:K70-K80.
6. Montanez A, Ruskin JN, Herbert PR, et al. Prolonged QTc in-
terval and risk of total and cardiovascular mortality and sud-
den death in the general population: a review and qualitative 
overview of the prospective cohort studies. Arch Int Med. 
2004;164(9):943-948.
7. Astrom-Lilja C, Odeberg JM, Ekman E, Hagg S. Drug-induced 
torsades de pointes: a review of the Swedish pharmacovigilence 
database. Pharmacoepidemiol Drug Saf. 2008;17:587-592. 
8. Tisdale JE, Wroblewski HA, Overholser BR, Kingery JR, Tru-
jillo TN, Kovacs RJ. Prevalence of QT interval prolongation in 
patients admitted to cardiac care units and frequency of subse-
quent administration of QT interval prolonging drugs. Drug Saf. 
2012;35(6):459-470. 
9. De Bruin ML, Langendijk PN, Koopmans RP, et al. In-hospi-
tal cardiac arrest is associated with use of non-antiarryhthmic 
QTc-prolonging Drugs. Br J Clin Pharmacol. 2007;63:216-223. 
R H O D E  I S L A N D  M E D I C A L  J O U R N A L M A R C H  2 0 1 3 40
CONTRIBUTIONS
Psychotropic Polypharmacy and QTc
The risk of QTc prolongation with antipsychotics and 
antidepressants is typically dose related.1,4,5,10 Therefore any 
combination of medications which results in elevated con-
centrations of antidepressants or antipsychotics increases 
the likelihood of QTc prolongation. Conversely, any psycho-
tropic that increases the concentration of non-psychotropic 
QTc prolonging medications increases the risk of drug in-
duce arrhythmia. Additionally, the risk of sudden cardiac 
death is increased in patients on multiple QTc prolonging 
medications, whether the psychotropics are combined with 
other QTc prolonging psychotropic or non-psychotropic 
medications. Thus careful consideration should be given to 
utilization of psychotropic polypharmacy and combinations 
of psychotropics and non-psychotropic medications.
Monitoring
Psychotropic drugs are known to affect the QTc interval 
and should be utilized with caution in patients with risk 
factors such as age >65, female gender, congenital long QTc 
syndrome, electrolyte abnormalities, polypharmacy and pre-
existing cardiac disease.1,13-15 For relatively healthy patients 
without preexisting risk factors, routine ECG monitoring 
should be considered for those with episodes of blackouts, 
fainting, seizures, or with unexplained lightheadedness, 
palpitations or dizziness.15 A baseline ECG should be consid-
ered in patients who are on multiple QTc prolonging medi-
cations or on high risk medications such as thioridazine. An 
ECG recording should be obtained for patients with any risk 
factors before treatment with a QTc prolonging psychotro-
pic is started and once the medications are at steady state. 
If the QTc is mildly elevated consider lowering the dose or 
utilizing another agent with less potential for QTc prolon-
gation. In patient whose QTc exceeds 500 milliseconds or 
whose QTc increases >60 milliseconds when starting a new 
psychotropic consider discontinuation of QTc prolonging 
psychotropics or switching to agents with a lower propensi-
ty for QTc prolongation. Electrolytes should be monitored 
in patients taking diuretics or those with severe diarrhea, 
vomiting or other risk factors for electrolyte imbalances. 1,13-14 
TREATMENT RECOMMENDATIONS
The risk of TdP is low in patients who are relatively healthy 
without cardiac disease. Therefore, for patients who do not 
have other risk factors, it is reasonable to use psychotropic 
medications that may prolong the QTc. For patients with pro-
longed QTc of <500 milliseconds at baseline, psychotropic 
medications are a reasonable treatment with ECG monitoring. 
Since the risk is highest during the first 90 days after start-
ing a medication, healthy patients on a stable regimen with 
a prolonged QTc of < 500 milliseconds can be continued 
on their current medication regimen. If the patient devel-
ops other risk factors, ECG is a useful tool for reevaluat-
ing the medication regimen. If the dose of a QTc prolonging 
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